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Although there were only 7 patients with FGFR2 
fusion in our trial, none of whom had an objec-
tive response, we note that the disease control 
rate in this group was 71%, which is similar to 
that in the overall trial population. Having said 
that, more information is needed to understand 
the clinical benefit of erdafitinib both in patients 
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Nintedanib for Systemic Sclerosis–Associated Interstitial  
Lung Disease
To the Editor: In the Safety and Efficacy of 
Nintedanib in Systemic Sclerosis (SENSCIS) 
trial, Distler et al. (June 27 issue)1 report that 
the annual rate of decline in forced vital capac-
ity in patients with interstitial lung disease 
(ILD) associated with systemic sclerosis was 
lower among those who received nintedanib 
than among those who received placebo. The 
answers to several important questions would 
better define to whom this result applies. Are 
the patients who have more fibrosis than 
ground-glass opacities on high-resolution com-
puted tomographic (CT) scans the ones who 
will benefit the most from nintedanib, as shown 
in trials involving patients with idiopathic pul-
monary fibrosis?2 Is the effect of nintedanib 
similar in patients with a predominant ground-
glass pattern on high-resolution CT scans and 
in those with a predominant fibrotic pattern? Is 
the effect of nintedanib, given its antiinflam-
matory properties in preclinical trials,3 similar 
to that of mycophenolate in patients with pre-
dominantly ground-glass opacities? We hope 
that the authors can provide clinicians with 
this information to better characterize the type 
of patients with ILD associated with systemic 
 sclerosis who will benefit the most from nin-
tedanib.
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To the Editor: Distler et al. showed that ninte-
danib has an antifibrotic effect in patients with 
ILD associated with systemic sclerosis. Appar-
ently, nintedanib did not reduce extrapulmonary 
manifestations of systemic sclerosis. However, in 
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many cases, nintedanib caused diarrhea, nausea, 
vomiting, or weight loss. This prompts the ques-
tion of whether the patients had any overall im-
provement.
Systemic sclerosis is a disease in which gastro-
intestinal manifestations are common, resulting 
in a decreased quality of life.1 Weight loss may 
be rapid and difficult to manage and is associ-
ated with poor survival.2 More precise informa-
tion on the gastrointestinal toxicity of ninted-
anib would be valuable. What are the data on 
weight loss and gastrointestinal morbidity? Fur-
thermore, we would have liked to learn which 
adverse effects led to drug withdrawal in the 46 
of 288 patients who received nintedanib, such as 
was reported in the INPULSIS trial.3 If ninte-
danib attenuates the decline of the forced vital 
capacity in patients with systemic sclerosis at the 
expense of worsened gastrointestinal morbidity, 
then the overall benefit for such patients remains 
to be proven.
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The authors reply: In reply to Moran-Mendoza 
et al.: patients were eligible for inclusion in the 
SENSCIS trial if they had features consistent with 
ILD associated with systemic sclerosis on a high-
resolution CT scan, with an extent of fibrotic in-
terstitial lung disease of at least 10%. Among the 
patients with available data, 42 of 283 (14.8%) in 
the nintedanib group and 36 of 282 (12.8%) in the 
placebo group did not have ground-glass opaci-
ties on high-resolution CT. Post hoc analyses 
showed no heterogeneity in the treatment effect 
of nintedanib as compared with placebo on the 
rate of decline in forced vital capacity in sub-
groups defined according to the presence or ab-
sence of ground-glass opacities (P>0.05 for treat-
ment-by-time-by-subgroup interaction). To date, 
no heterogeneity has been found in the treatment 
effect of nintedanib in subgroups defined ac-
cording to a variety of baseline characteristics, 
which suggests that nintedanib is effective in re-
ducing the progression of ILD associated with 
systemic sclerosis across a broad population of 
patients. However, we caution against overinter-
preting multiple subgroup analyses as a means 
of identifying independent predictors of treat-
ment response.
In reply to Andréasson et al.: in the SENSCIS 
trial, diarrhea, nausea, and vomiting were the 
most frequent adverse events among the patients 
who received nintedanib and were the adverse 
events that most frequently led to treatment dis-
continuation. However, nintedanib was discon-
tinued prematurely by only 20 patients (6.9%) 
because of diarrhea, 6 patients (2.1%) because of 
nausea, and 4 patients (1.4%) because of vomit-
ing; these outcomes suggest that the guidance 
provided to investigators on the management of 
adverse events through the use of antidiarrheal 
treatment, hydration, and dose adjustment was 
effective in enabling patients to continue treat-
ment. Weight loss was reported as an adverse 
event in 34 patients (11.8%) in the nintedanib 
group and in 12 patients (4.2%) in the placebo 
group and led to discontinuation of the trial 
drug in 1 patient in the nintedanib group. An-
dréasson et al. raise the question of the ratio of 
risk to benefit. We believe that nintedanib pro-
vides a benefit in patients with ILD associated 
with systemic sclerosis by reducing the rate of 
progression of interstitial lung disease, which is 
the leading cause of death in these patients.1 Our 
data show that the side effects of nintedanib did 
not result in treatment discontinuation in most 
patients.
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New Guidelines for Statistical Reporting
To the Editor: Harrington et al. (July 18 issue)1 
describe new guidelines for statistical reporting in 
the Journal. One important change is that P values 
may not be reported if a method for adjustment 
for multiple hypothesis testing was not prespeci-
fied. Assuming there is complete reporting of all 
tests that were conducted, this policy appears to 
address a concern that investigators may select a 
method that yields the most favorable results 
(e.g., one that maximizes the number of adjusted 
P values <0.05 or minimizes the minimum ad-
justed P value). We investigated these strategies 
in simulation studies using six methods that 
control family-wise error (Bonferroni, Holm, 
Hommel, Hochberg, Sidak single-stage, and Sidak 
step-down) and three that control false discovery 
rates (Benjamini–Hochberg, Benjamini–Yekutieli, 
and two-stage Benjamini–Hochberg). Both of the 
post hoc adjustment strategies, which involve a 
high degree of selection, maintain an equivalent 
level of control of the family-wise error rate un-
der a range of number of tests and correlations 
Table 1). This is not the case when the adaptive 
Benjamini–Hochberg method is included. In con-
junction with appropriate presentation of esti-
mates and confidence intervals, the Journal might 
allow post hoc testing with the use of these nine 
methods.
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The author replies: Betensky and Newberger’s 
simulation shows that when a set of comparisons 
(i.e., a family of tests) is well defined in advance, 
the arbitrary choice of a post hoc procedure may 
not lead to inflated type 1 or false discovery 
probabilities. Their assumption requires that the 
comparisons shown in a manuscript be the only 
ones examined for possible inclusion.
Betensky and Newberger’s proposal presents 
some operational challenges as well. Many studies 
in the medical literature aim to provide evidence 










0 0.052 0.052 0.053
0.5 0.032 0.037 0.037
0.9 0.019 0.026 0.026
50
Correlation
0 0.046 0.046 0.047
0.5 0.029 0.034 0.034
0.9 0.015 0.025 0.025
100
Correlation
0 0.051 0.052 0.053
0.5 0.027 0.034 0.034
0.9 0.010 0.022 0.022
*  For each replication, post hoc procedures were chosen that either maximized 
the number of adjusted P values <0.05, or equivalently, minimized the minimum 
adjusted P value, simulating a setting in which the data analyst chooses the 
most favorable approach. Each replicate simulated P values from cumulative, 
normal, distribution-function transformations of equicorrelated multivariate 
standard normal distributions. Family-wise error rate procedures include Bon-
ferroni, Hochberg, Hommel, Sidak single-stage, and Sidak step-down. False-
discovery rate procedures include Benjamini–Hochberg, Benjamini–Yekutieli, 
and two-stage Benjamini–Hochberg. The simulation used the mt.rawp2adjp 
function in a multiple-test package in Bioconductor and the p.adjust function 
in R (Hommel procedure only).
Table 1. Estimated Family-wise Error Rate (10,000 Repetitions)  
under a Complete Null Hypothesis.*
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